Bio or Pharma — Which side are you on?

With healthcare reform, biosimilar legislation and pharma-industry taxation among the topics perking along in Washington this summer, it’s important for life sciences companies to present a unified front to legislators. Thus, it doesn’t appear to be a casual decision by […]

Read More